However, SLE treatment failures have been observed even after targeting B-cell-surface antigen, which led to alternative targets of B-cell activation, such as B lymphocyte stimulator (BlyS) or B cell-activating factor (BAFF) [14]. Belimumab, a monoclonal antibody against BlyS has successfully completed phase III trials [14, 15]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.